RBC Capital analysts initiated coverage on Eli Lilly and Company (NYSE:LLY) with a Outperform rating on February 25, 2026.
Eli Lilly and Company operates in the Healthcare sector. The stock currently trades at $1052.20 with a market capitalization of $906.5B. The stock has gained 24.2% over the past 52 weeks.
Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Eli Lilly and Company.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
